EyesOn Risk Management In Action

Although GSK and Takeda are facing very different circumstances, both companies are flexing their Risk management skills to remain competitive.

GSK Makes Its Largest Oncology Bet in Years

GSK's agreement to acquire Nuvalent for approximately $10.6 billion represents more than just another biotechnology acquisition. It is one of the clearest examples of a company proactively reshaping its future revenue base before facing a significant patent cliff.

For several years, investors have questioned how GSK would replace revenues expected to decline as dolutegravir, one of the company's cornerstone HIV therapies, approaches loss of exclusivity between 2028 and 2030. Rather than waiting for that pressure to materialize, GSK has accelerated its oncology ambitions through a transaction that immediately adds multiple late-stage assets.

More Than One Product

Unlike many acquisitions centered on a single promising therapy, Nuvalent provides GSK with a broader precision oncology platform. The acquisition includes:

• Zidesamtinib

  • ROS1 inhibitor

  • FDA decision expected in September

  • Potential first- and later-line treatment for ROS1-positive non-small cell lung cancer (NSCLC)

• Neladalkib

  • ALK inhibitor

  • FDA decision expected in November

  • Positioned to compete across first- and second-line ALK-positive NSCLC

• In addition, Nuvalent brings:

  • A Phase 1 HER2 inhibitor

  • Earlier-stage precision oncology programs

  • An experienced targeted oncology development organization

Why These Targets Matter

Both ROS1 and ALK mutations occur in relatively small percentages of NSCLC patients:

• ROS1: approximately 1–3%

• ALK: approximately 3–5%

However, these patients often remain on therapy for years because targeted kinase inhibitors can produce durable responses. As a result, these markets generate unusually attractive lifetime commercial value despite relatively small patient populations.

Competitive Positioning

Nuvalent is not entering an empty market.

The company must compete against established therapies including:

ROS1

• Pfizer's Xalkori

• Roche's Rozlytrek

• Bristol Myers Squibb's Augtyro

ALK

• Roche's Alecensa

• Pfizer's Lorbrena

Nuvalent believes it can differentiate through:

• Improved central nervous system penetration

• Greater durability

• Better tolerability

• Reduced neurological adverse events

Those claims will ultimately need to be validated commercially. However, they illustrate how critical it is for the next generation of targeted therapies to demonstrate meaningful differentiation—not simply non-inferiority.

Looking At the Full Portfolio

GSK is simultaneously advancing:

• B7-H3 antibody-drug conjugate risvutatug rezetecan

• Multiple immuno-oncology programs

• Precision medicine initiatives

If approved, zidesamtinib and neladalkib would provide commercial infrastructure that supports future oncology launches.

Takeda's Challenge Extends Beyond Litigation

Recently, Takeda found itself responding to one of the largest legal setbacks seen in the pharmaceutical industry in recent years. A U.S. federal jury found the company liable in a pay-for-delay antitrust case involving its constipation therapy Amitiza, awarding approximately $885 million in damages. Under U.S. antitrust law, that amount could potentially increase to approximately $2.5 billion.

Although Takeda plans to appeal and continues to dispute the ruling, accounting rules required the company to recognize the potential exposure in its financial statements.

Financial Impact

Takeda's previously reported $1.19 billion profit for fiscal year 2025 became a $949 million net loss after recording the litigation provision.

Importantly, however, the underlying business remained relatively unchanged.

Annual revenue remained approximately $28 billion, and management reaffirmed its broader commercial outlook.

That distinction matters. The legal issue significantly affects reported earnings, but management argues it does not fundamentally alter the company's operating trajectory.

Continuing to Invest Despite Uncertainty

Takeda is addressing this legal uncertainty while simultaneously executing a broad corporate transformation.

Management recently announced plans to eliminate more than 4,500 positions during fiscal 2026 as part of a restructuring program expected to generate approximately $1.26 billion in annualized savings by 2028.

At the same time, Takeda continues preparing for several important product launches, including:

• Zasocitinib for psoriasis

• Rusfertide for polycythemia vera

• Oveporexton for narcolepsy

These programs represent important future growth drivers that could help offset legal and patent-related pressures.

Takeda's situation illustrates the need to have the flexibility to absorb / manage unexpected events without compromising long-term strategic priorities. Risk-managment is a key lever to maintaining a competitive advantage.

More Details:

PharmaTell

PharmaTell

Pharmaceutical Technology